Ustekinumab is a human interleukin-12 and -23 antagonist indicated for multiple chronic inflammatory diseases. A biosimilar is a biological product that is approved based on data demonstrating that ...

Samsung Bioepis has announced US Food and Drug Administration (FDA) approval for PYZCHIVA (ustekinumab-ttwe / SB17) as a biosimilar to Stelara (ustekinumab). The approval includes subcutaneous ...

As previously reported, litigation between Johnson & Johnson and Janssen (“J&J”) and Samsung Bioepis (“Samsung”) involving Samsung’s ...

The approval was based on a totality of evidence, including data from a phase 3 study (ClinicalTrials.gov Identifier: NCT04967508) that compared the efficacy and safety of Pyzchiva to the reference ...

Please provide your email address to receive an email when new articles are posted on . Pyzchiva, an ustekinumab biosimilar, is approved for all indications of the reference medicine, including ...

Expected to be among first wave of ustekinumab biosimilars to launch in US Basel, July 1, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and ...

(RTTNews) - Sandoz Group AG (SDZNY), a Swiss maker of generic and biosimilar medicines, announced Monday that the US Food and Drug Administration has approved biosimilar Pyzchiva (ustekinumab-ttwe), ...

(RTTNews) - Sandoz Group AG (SDZNY.OB), a Swiss company that focuses on generic pharmaceuticals and biosimilars, today announced the approval of Pyzchiva. The FDA has granted approval to Pyzchiva, a ...

Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered ...

PYZCHIVA’s licensing period will begin on February 22, 2025, in the United States, based on the settlement and licensing agreement with Janssen Biotech Inc. PYZCHIVA will be commercialized by Sandoz ...

Autoinjector includes unique features to improve comfort, independence and convenience for patients with chronic inflammatory diseases [1-10] Launch strengthens Sandoz biosimilar leadership position ...

Sandoz is releasing Pyzchiva (ustekinumab) across Europe. Pyzchiva is approved for treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for ...